Study identification

PURI

https://redirect.ema.europa.eu/resource/1000000062

EU PAS number

EUPAS1000000062

Study ID

1000000062

Official title and acronym

CROSSROADS-1: Treatment Outcomes among Tezspire Users: A Claims Data Study (20230159)

DARWIN EU® study

No

Study countries

United States

Study description

This will be a descriptive, retrospective cohort study conducted utilizing the IQVIA PharMetrics® Plus database to assess the reduction of asthma exacerbations and healthcare resource utilization among Tezspire users.

Study status

Ongoing
Research institutions and networks

Institutions

Amgen
United States
First published:
21/02/2024
Institution
IQVIA
United Kingdom
First published:
22/04/2024
InstitutionNon-Pharmaceutical companyENCePP partner

Contact details

Global Development Leader Amgen Inc.

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Amgen 100%
Study protocol
Initial protocol

Protocol-Published Amendment tezepelumab 20230159 1 .pdf

English (445.31 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable